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Identifying Recrudescent 
Plasmodium falciparum in Treated 
Malaria Patients by Real-time PCR 
and High Resolution Melt Analysis 
of Genetic Diversity
Khalid B. Beshir  1, Nouhoum Diallo2 & Colin J. Sutherland  1,3
Recurrent parasitaemia during follow up of clinical trials of antimalarial drug efficacy results from either 
recrudescence of parasites surviving treatment or from parasites newly emerging from the hepatic 
stage of infection. Nested PCR is used to distinguish these two possibilities and the technique is difficult 
to standardise. There is risk of both false positive and false negative results, leading to misclassification 
errors. The high-resolution melt (HRM) assay was developed with pairs of conserved primers targeting 
blocks of merozoite surface protein 1 and 2 (msp1 and msp2) genes, and polymorphisms were compared 
using sequence-confirmed Plasmodium falciparum DNA samples from laboratory isolates. In this 
study, the HRM dissociation profiles of msp1 and msp2 amplicons were determined and validated 
against parasite isolates from malaria patients. The msp1 and msp2 profiles of both laboratory and 
clinical isolates were reproducibly differentiated by HRM. These rapid assays are performed in a closed-
tube system, and so avoid cross-contamination while increasing throughput, which are two major 
advantages. The HRM assays offer significant gains in simplicity, speed and interpretation of results, 
and reduced analysis cost, for studies that require discrimination of parasite clones. Assay performance 
in large-scale studies utilizing DNA samples derived from filter-paper bloodspots should now be 
evaluated.
Plasmodium falciparum is the most virulent of the six Plasmodium species that cause malaria in humans, being 
responsible for high mortality and morbidity, particularly in Africa. Efforts to control and eliminate malaria have 
been hampered by the emergence of drug resistant parasites1, but our ability to track and control resistance is 
also hampered by the high genetic diversity of P. falciparum. Further, to accurately estimate true drug efficacy 
in clinical trials of antimalarial drugs, recurrent infections seen after drug treatment need to be identified either 
as new infections arising from the liver or as recrudescent parasites persisting from the original infection. A 
PCR-correction method is generally deployed to distinguish between the two. In addition, ex vivo and in vitro 
studies to identify drug resistant parasites in complex infections also need to identify the constituent parasite 
clones in an infection or isolate in order to accurately capture the emergence of minor clones in the subsequent 
growth of parasites2,3, as is also seen in vivo4. This requires the identification of clones in paired samples, before 
and after treatment, and determining whether they are the same clones5.
One tool commonly used to distinguish between newly emergent and recrudescent parasites is conventional 
nested-PCR and gel electrophoresis detection. In this genotyping method, the genes that code the surface antigen 
loci of merozoite surface protein 1 and 2 (msp1,msp2) and glutamate rich protein (glurp) are amplified using 
sequence specific primers in a nested-PCR6. The recurrent infection is categorized by comparing the size of 
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polymorphic repeat regions in these genes before (day 0) and after treatment (day of failure). If fragment sizes 
differ, the recurrent infection is categorized as a new infection, but if the post-treatment analysis produces the 
same fragment sizes as before treatment, these are considered recrudescent parasites, implying that treatment 
failure has occurred. In multi-clonal infections, minority clones constituting a small proportion of the total bio-
mass might fall below the detection limit of the genotyping method and be missed by PCR-based detection due to 
competition for primers or other constituents of the reaction mix by the more abundant clones7. This was resolved 
by genotyping at extra time points on day 1 and day 2 post-treatment as well as at the follow-up time-point prior 
to the day that microscopically detected parasite recurrence occurred5,8. Using this approach, studies of treated 
malaria patients in Kenya and Tanzania showed the presence of additional malaria clones, differing from those 
at day 0 and day of failure resulting in re-classification of many recurrent infections as recrudescent infections 
in these extended analyses5,8,9. However, this approach requires significantly more effort, and current methods 
for determining different clones such as nested-PCR, microsatellite and DNA sequencing are labour-intensive, 
time-consuming and are prone to contamination. In addition, gel electrophoresis-based methods discriminate 
clones based on size differences alone and cannot detect sequence variation. In this study, a real-time quantitative 
PCR (qPCR) was developed with (HRM) method analysis, which is sensitive to both amplicon length and base 
composition, to identify distinct P. falciparum msp1 and msp2 genotypes.
Results
Primer optimization and validity of the assay. Alignments of msp1 and msp2 genes from 3D7, Dd2, 
7G8, K1, FCR3, R033 and HB3 were assessed to design oligonucleotide primers that amplify the conserved 
regions (data not shown). To establish the specificity of the oligonucleotide primers and optimize the PCR condi-
tions, 3D7 DNA obtained from laboratory-cultured parasites were initially used. Amplification of msp1 resulted 
in one minor peak and the major peak was retained in melt curve analysis but only the major one in HRM nor-
malized graph windows. The msp2 genotyping of 3D7 DNA, however, unexpectedly produced two major melt 
peaks and HRM amplification curves each. It was first thought this resulted from the presence of two amplicons 
due to contamination. Further repeats of the msp1 and msp2 HRM analyses with a different source of DNA again 
gave two amplification curves for msp2, and fractionation of PCR products by gel electrophoresis confirmed 
that. Both msp1 and msp2 generated single band each of the predicted size. To rule out any inherent problems of 
the assays, we used uMELT software10 to predict the HRM curve of msp1 and msp2 gene fragment sequence of 
3D7. The software correctly predicted one major and one minor curve for msp1 and two major curves for msp2 
suggesting that this pattern does indicate two amplicons, but rather it is due to a bimodal melt of the double 
stranded DNA (dsDNA) where the base composition if not uniform throughout. The dsDNA melts in transition 
with regions of the amplicon that are more stable (e.g., G/C rich) melting later. These stable regions maintain their 
dsDNA configuration until the temperature is high enough to cause melting of the stable region, resulting in a 
bimodal melt profile even though only one amplicon is produced in the reaction.
To determine the limit of detection of the msp1 and msp2 HRM assays, 3D7 DNA at different parasite densities 
(3–0.00003%) was amplified. The assay detected as low as 1.5 parasites per µl with GCP of 77.44% and 62.44% for 
msp1 and msp2, respectively, relative to a 3D7 DNA sample at 1500 parasites per µl. GCP estimates increased to 
92.32% and 78.41% for msp1 and msp2 genotypes respectively when 15 parasites per µl (0.0003% parasitaemia) 
were used. We then chose the 3D7 DNA sample with 15 parasites per µl, which is closer to limit of detection of 
parasites by expert or reference laboratory microscopy, to determine the inter-assay coefficient of variation (CV). 
The mean ± SD inter-assay CV (n = 35) for msp1 and msp2 was 93.15 ± 5.99 and 86.45 ± 9.47 respectively (Fig. 1).
In an analysis of monoclonal parasite preparations, a distinct HRM amplification curve was produced for each 
of the five different clones (3D7, Dd2, 7G8, K1 and R033) using msp1 and msp2 genotypes (Fig. 2). DNA samples 
with 0.3%, 0.03% and 0.003% parasitaemia generated mean GCP of 76.8%, 78.2%, 99.3%, 95.5% and 88.9% for 
the 5 strains, respectively, when genotyped with msp1 primers and mean GCP of 78.2%, 74.5%, 86.1%, 61.5% and 
87.9%, when genotyped with msp2 primers. The clones with lower melting temperature (Tm) (due to a shorter 
nucleotide sequence) such as 7G8, K1 and R033 in msp1 genotype were less affected by parasitaemia difference 
compared to the clones with higher Tm (longer nucleotide sequence) such as 3D7 and Dd2 (data not shown). The 
Figure 1. Normalized temperature-shifted HRM curves of msp1 and msp2 genes of P. falciparum 3D7 DNA. 
Each target was amplified in 35 tests with parasite DNA from a culture of 3D7 at 15 parasites per µl. The analysis 
software classified all samples as one genotype with (Genotype Confidence Percentage (GCP) of 71.9–99.5% for 
msp1 and 71.8–99.3% for msp2 genotype. Left: msp1. Right: msp2.
www.nature.com/scientificreports/
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minor peak observed in 3d7 msp1 genotyping was also observed in all other laboratory isolates and was conse-
quently excluded from HRM analysis.
Detection of mixed laboratory clones. To study the sensitivity of the assay when mixed clones are pres-
ent in a sample, we mixed Dd2 and 7G8, and Dd2 and K1 in different ratios. As predicted, msp1 genotype as well 
as the msp2 genotype for Dd2 produced two distinct HRM curves when two clones were mixed (Fig. 3). The msp2 
genotype produced two HRM curves and three melt curves when two clones were present in the sample. These 
results have also be been confirmed in the melt curve analysis window (Table 1). If the parasitaemia of a particular 
laboratory strain in the mixture increases the HRM curve shifts toward the HRM curve of that particular strain. 
In all samples, the parasitaemia was adjusted to a maximum of 0.3% (15,000 parasites per µl) and minimum of 
0.0003% (15 parasite per µl). Samples containing the same ratios of genotypes but different parasite density gen-
erally gave similar results but with smaller GCP. However, the higher the Tm value differences between mixed 
clones, the lower the GCP when calling the genotype similarity.
Patient samples. We genotyped paired pre- and post-treatment blood samples from five Hospital for 
Tropical Diseases (HTD) patients, and one additional unpaired pre-treatment sample. We investigated whether 
the assay accurately detects the number of clones in each sample and correctly classifies before and after treatment 
samples as the “same” or “different” infections. The HRM/melt curves generated by msp1 and msp2 genotypes 
for each patient are presented in Figs 4 and 5. With the exception of HL1210 and HL1211, all patient samples 
on post-treatment carried an extra HRM/melt curve when genotyped by msp1 compared to corresponding 
pre-treatment samples (Fig. 4). Generally, the additional HRM peak in the post-treatment samples displayed 
lower fluorescence intensity compared to other peaks, suggesting a minor clone, which was below the detec-
tion limit of the assay in the pre-treatment samples. This difference was reflected in the genotype calling of the 
paired samples, where HL1204 and HL1209 were classified as the “same” infection with a genotype confidence 
percentage (GCP) of 78.6% and 62.3%, respectively, indicating moderate similarity to the pre-treatment sample, 
compared to low similarity for HL1205 (<50%) (Table 2). HL1210 and HL1211 produced very similar HRM/melt 
curves for pre and post treatment samples, and as a result, their GCP were 90.6% and 93.1% respectively, showing 
much greater similarity between the two time points than the patients with an extra clone in post-treatment sam-
ples. On the other hand, msp2 genotyping produced the same HRM/melt curve in all paired patients samples with 
the exception of HL1205, where an extra curve was observed (Fig. 5). Consequently, the GCP was much higher 
(87.5–97.5%) compared to their corresponding GCP of patient samples obtained by msp1 genotyping. Paired 
DNA samples of HL1205 patient had GCP of less than 50% confirming the GCP obtained by msp1 genotyping.
The allelic family of the DBS field samples was determined relative to the HRM melt curve of the positive con-
trols with known allelic family (RO33 for msp1 or Dd2 for msp2 and K1 and 3D7 for both), which represent the 
three different HRM melt curve observed in the initial validation experiment. Any sample within 0.2 °C degree of 
the sample with known HRM melt curve belongs to the same clone (Supplementary Fig. S1A–C).
All DBS field samples collected on day 0 showed the same HRM melt curve (the same Tm value) using both 
msp1 and msp2 assays compared to the samples collected 7 days later (Fig. S1A–C). On the other hand, the day 14 
sample of one child showed one less clone compared to day 0 and day 7 while the day 21 sample of another child 
had one different clone compared to day 0 and 7 (Supplementary Table S1). The msp1 and msp2 HRM melt curve 
Figure 2. Normalized HRM analysis of msp1 (a1–3) and msp2 (b1–3) genotypes in 5 parasite lines. HRM 
amplification curves (a1 and b1), difference curves (A2 and B2) and melting curves (A3 and B3) for 5 P. 
falciparum laboratory strains are shown. K1 is deployed as the comparator genotype in (a2 and b2). dF/dT: 
negative derivative of change in florescence.
www.nature.com/scientificreports/
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results were similar to clones generated by gel-based electrophoresis. One sample (K011) on day 28 was negative 
by msp1 but showed similar HRM melt curve on msp2 though slightly different Tm was observed (84.2 on d0 and 
83.8 on day 28). However, the normalized HRM curve classified the two samples as “different”. This is consistent 
with the gel-based PCR, which generated different clones on d0 (K1 and RO33) and d28 (K1 and MAD20) sug-
gesting a possible new infection (Supplementary Fig. S2).
To confirm the above HRM melt curve analysis, a GCP analysis was performed on all field samples. Samples 
collected before treatment and 7 days after treatment were classified as the “same” with a mean GCP of 85% 
(64–99%) for msp1 and 82% (61–99%) for msp2 in all samples. Samples collected after day 7 (day 14, 21 and 28) 
were classified as “different” with a GCP of less than 50% relative to day 0 sample. This was in complete agreement 
with the gel-based PCR results (Supplementary Fig. S2).
GCP cut-off value for distinguishing between recrudescence and new infection. When com-
pared to DNA prepared from a 3D7 culture at 3% parasitaemia, DNA from the lowest parasitaemia 3D7 culture 
(0.0003%) produced GCP estimates of 77.44% and 62.44% for msp1 and msp2 respectively. When Dd2 and 7G8 
were artificially mixed, DNA from a 10:1 to 1000:1 mixtures at 0.3% parasitaemia generated a GCP estimate 
for msp1 and msp2 of >50% in comparison with a 1:1 mixture at the same parasite density (Table 1). This GCP 
estimate is a better reflection of actual field isolates, and fits with the WHO definition of a new infection, which 
Figure 3. msp1, msp2 HRM discrimination of artificial mixes of parasite clones at different ratios. Normalized 
temperature-shifted HRM amplification curves for msp1 (a1,c1 and e1) and msp2 (b1 and d1) and their 
corresponding melt curves (a2,b2,c2,d2 and e2) are shown for Dd2, K1 and 7G8 laboratory lines, and mixes of 
two strains at the ratios shown.
www.nature.com/scientificreports/
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requires that all alleles, in one or all loci tested, should be different in both time-points. Therefore, we opted to use 
GCP of 50% as a cut off value to distinguish recrudescence from new infections. This cut-off value was applied for 
the paired pre- and post-treatment patient samples and accurately classified four of the five as the “same” infec-
tions with a satisfactory GCP (≥62.3%). This was expected as the paired samples were obtained before and 13–48 
hrs after antimalarial treatment and new infections are not expected at this time.
Genetic diversity study. To assess the general relevance of the assay for applications requiring analysis of 
genetic diversity, the difference graph was used to cluster clones based on their similarities. Using the standard 
gel-based msp1 and msp2 genotyping, parasite isolates are broadly classified into K1, MAD20 and R033, and FC 
and IC/3D7 sub family clones respectively. Since the Tm value for the K1 clone was found to lie in the middle of 
the range of values across all laboratory isolates tested, this clone was used as a calibrator and the software calcu-
lated the florescence signal of each clone relative to the signal of K1 and to generate a difference graph (Fig. 2). 
The approach correctly clustered the msp2 clones into two groups, cone comprising 3D7, 7G8 and R033, and the 
second represented by Dd2. These groups correspond to IC/3D7 and FC sub family alleles originally described by 
Snounou and colleagues respectively6,7. The msp1 difference graph clustered the clones into three groups contain-
ing 3D7, Dd2 (MAD20), 7G8 (R033). In gel-based discrimination, 3D7 and K1 are grouped together but in the 
HRM assay, they cluster into different groups, reflecting difference in the DNA sequence and length. Interestingly, 
the patient DNA samples HL1204 and HL1209, HL1205 and HL1212, and HL1210 and HL1211 clustered into 
7G8/R033, Dd2 (MAD20) and 3D7 allele types respectively with GCP ranging from 42.6% to 78.2% when gen-
otyped with msp1. When genotyped with msp2 HL1204, HL1210 and HL1211 clustered into IC/3d7 sub family 
clones while HL1205, HL1209 and HL1212 clustered in both IC/3D7 and FC type clones suggesting that both 
alleles were present in the samples. This has been previously reported for these isolates using gel electrophoresis, 
where the samples contained more than 3 or more clones of FC type and more than 1 or more clones of IC/3D7 
type3. Using HRM, the classification of parasite clones into clusters of sub-families takes 3–4 hrs compared to 1–2 
days using PCR and gel-electrophoresis methods (Fig. 6).
Laboratory 
strain
Mix 
ratio
Genotype 
called by the 
software
Msp1 Msp2
Mean 
GCP * Tm*
Mean 
GCP* Tm*
3D7 — 3D7 99.3 86.0 99.9 84.0 and 86.5
Dd2 — Dd2 97.5 86.4 99.7 83.50
7G8 — 7G8 99.7 83.3 99.7 84.3 and 87.3
K1 — K1 99.9 84.0 and 84.3 99.7 82.8 and 83.8
R033 — R033 99.9 82.9 99.5 84.3 and 87.3
Dd2:7G8 1:1 Dd2/7G8 99.6 83.2 and 86.5 98.7 83.9 and 86.9
10:1 Dd2/7G8 91.8 83.2 and 86.5 74.4 83.9 and 86.9
25:1 Dd2/7G8 88.3 83.2 and 86.5 68.4 83.9 and 86.9
50:1 Dd2/7G8 76.5 83.3 and 86.6 62.7 83.9 and 86.9
100:1 Dd2/7G8 73.9 83.2 and 86.5 62.4 83.9 and 86.9
500:1 Dd2/7G8 63.15 83.2 and 86.5 59.5 83.9 and 86.9
1000:1 Dd2/7G8 61.4 83.2 and 86.5 52.88 83.9 and 86.9
1:1000 Dd2/7G8 99.3 83.2 and 86.3 56.3 81.9 and 84.9
1:500 Dd2/7G8 62.8 83.2 and 86.3 61.2 81.9 and 84.9
1:100 Dd2/7G8 73.2 83.2 and 86.3 64.5 81.9 and 84.9
1:50 Dd2/7G8 78.2 83.3 and 86.3 70.2 81.9 and 84.9
1:25 Dd2/7G8 89.2 83.2 and 86.3 73.6 81.9 and 84.9
1:10 Dd2/7G8 91.2 83.2 and 86.3 78.5 81.9 and 84.9
1:1 Dd2/7G8 99.3 83.2 and 86.3 97.9 81.9 and 84.9
1:1 Dd2/K1 99.8 84.0 and 86.0 — —
10:1 Dd2/K1 93.9 84.0 and 86.0 — —
25:1 Dd2/K1 89.7 84.0 and 86.0 — —
50:1 Dd2/K1 86.5 84.0 and 86.0 — —
100:1 Dd2/K1 83.5 84.0 and 86.0 — —
500:1 Dd2/K1 73.2 84.0 and 86.0 — —
1000:1 Dd2/K1 71.4 84.0 and 86.0 — —
Table 1. Mean melting peak and mean GCP* of single and mixed laboratory strains. *For samples with a 
single allele, the mean GCP estimates agreement between duplicate tests while the mean GCP for the mixtures 
is estimated from 2 mixtures of Dd2 and 7G8 at the ratio shown, relative to the 1:1 mixture. **Tm: melting 
temperature; this is estimated by the rotor-gene 6000 analysis software (version 1.7). Mixture clones of Dd2 and 
K1 was not done as both belong to the same allelic family.
www.nature.com/scientificreports/
6SCIEnTIFIC REPORTS |  (2018) 8:10097  | DOI:10.1038/s41598-018-28179-2
Discussion
Genotyping of the msp1 and msp2 loci has been deployed to assess multiplicity of infection, to evaluate 
strain-specific selection in vaccine efficacy studies, to estimate the genetic diversity of P. falciparum in population 
genetic studies, and to distinguish between recrudescent and novel genotypes in recurrent infections occurring 
in participants treated for malaria in the course of antimalarial drug efficacy trials. These studies have most com-
monly used PCR and gel electrophoresis, for discrimination among different msp1 and msp2 alleles6,11. The spec-
ificity of PCR- identification of recrudescent infections can be improved by deploying multiple post-treatment 
time points5,9. However, if using the nested-PCR and gel-electrophoresis method, this approach is laborious, 
resource intensive and can cause difficulties in interpretation. The current study reports the development of 
real-time PCR based HRM technology for msp1 and msp2 genotyping a new tool for in vivo and in vitro drug 
and vaccine efficacy studies. HRM analysis is a closed tube approach for fast, accurate, high throughput geno-
typing and provides a simple method for PCR-correction. This eliminates the limitations of gel electrophoresis 
and subjective characterisation of the different alleles. Unlike electrophoresis, HRM can distinguish alleles based 
on differences in base composition, sequence and amplicon size, delivers quantitative estimate of allele similarity 
(GCP), and has been successfully evaluated for detection of drug resistance malaria parasites12.
The msp1 and msp2 HRM assays correctly discriminated alleles from five different single-clone laboratory 
isolates, those of polyclonal DNA samples derived from whole blood and DBS. The assays detected densities as 
low as 1.5 parasites per µl accurately, suggesting that the method is as sensitive as the nested-PCR electrophoresis 
method. However, the mixed clones evaluated were artificially prepared and the ability of HRM assays to precisely 
estimate the probability of missed alleles in natural field isolates remains to be determined. This was clear when 
paired patient samples were genotyped and analysed using HRM, where at least one allele was missed in two 
patient samples compared to the nested-PCR and gel electrophoresis method3. It is not clear whether this is due to 
an intrinsic sensitivity difference in detecting minor clones or the detection of false positive alleles by nested-PCR 
and gel electrophoresis, possibly due to amplicon contamination. HRM assays avoid contamination and risk of 
PCR product carry-over as the method is non-nested and uses a closed-tube readout.
Both msp1 and msp2 HRM genotyping identified one or more extra alleles in post-treatment samples from 
some of the patients. This was also observed previously when the same samples were genotyped by PCR and gel 
electrophoresis, suggesting that this is a general observation regardless of the PCR-based genotyping methods 
used3,13, best explained by changes in the relative abundance of the constituent circulating clones in vivo before 
and after treatment5,8. In polyclonal infections, these changes in relative abundance mean certain genotypes may 
remain undetected at one time point, but recur later leading to false classification. These minority clones are 
missed by PCR-based detection methods due to competition for primers or other constituents of the reaction 
mix by the more abundant clones7. In a study in Papua New Guinea, detection of minor clones decreased with an 
increase in multiplicity of infection, suggesting the dominance of major clones among PCR amplicons detected14. 
A similar study carried out in Uganda reported a higher probability of mixed infections in high transmission areas, 
and this affected classification of treatment outcomes15. A slow-clearing minority variant present but not detected 
at admission, could cause recrudescence but would be identified in the recurrent sample as a new infection, 
rather than recrudescence of parasite genotypes present at the time of treatment. This has recently been demon-
strated in a multiplicity of infection study to detect and quantify the markers of antimalarial drug resistance16. 
Therefore, the failure to detect minor alleles at day 0 is likely to lead to misclassification of some infections17. The 
data in this study and previous reports3,5,8 demonstrate that inclusion of the additional time points day 1, day 2 
and day before failure, in addition to pre-treatment and day of failure, improve specificity when determining the 
complexity and origins of recurrent infections.
One other strength of the HRM assay is that the clones are discriminated based not only on length but also 
sequence differences and this feature allows the HRM assay to overcome the resolution limitation observed in 
the gel electrophoresis-based methods6. This is particularly important in high transmission settings, where two 
distinct clones may generate PCR products with the same size but which differ in sequence. These will be indis-
tinguishable by gel electrophoresis. Others have attempted to resolve this by classifying any pair of samples that 
contain matched and unmatched alleles as new infections18, but this can clearly lead to underestimation of recru-
descence infections. WHO/MMV guideline states that, in treated malaria patients, “ a ‘re-infection’ [i.e. new 
infections] is a subsequent occurring parasitaemia in which all the alleles in parasites from the post-treatment 
sample are different from those in the admission sample, for one or more loci tested”19. This definition seeks to 
minimize misclassification error and maximize accuracy of classification.
One of the shortcomings of the HRM assays is that some of the msp1 and msp2 alleles generate more than one 
melting peak, due to the inherent two-phased nature their DNA melting profile. For distinguishing recrudescence 
from new infections, this shortcoming can be overcome as the HRM amplification curves of the samples before 
and after treatment are compared with each other, and any additional peak due to the inherent nature of DNA 
melting will be reflected in both samples. The interpretation of those melting peaks will be more challenging if 
the genotyping purpose is to study parasite diversity and complexity of infection, although we have shown that 
this can be overcome by including known comparators for both msp1 and msp2 genotyping. Measurement of the 
amplification signal of each clone relative to these comparators thus permits classification of allelic variants into 
clusters.
In addition to drug and vaccine efficacy studies, HRM genotyping can be applied in studies of parasite biology – 
for example, to assess parasite cloning experiments, and in monitoring the identity, integrity and clonality of prop-
agated parasite lines, if necessary direct from cryo-preserved material. The HRM method can also be deployed 
as tool for in vitro drug sensitivity studies, particularly for polyclonal parasite isolate in which a subset of geno-
types preferentially survive in vitro cultures, as this often reflect survival in in vivo therapeutic efficacy studies20. 
Our data warrant the large-scale evaluation of the performance of the real-time PCR and HRM approach on DNA 
samples derived from filter paper bloodspots collected in field studies.
www.nature.com/scientificreports/
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Materials and Methods
Plasmodium falciparum DNA strains and field samples. Parasite DNA from malaria cases treated at 
the Hospital for Tropical Diseases (HTD), London, UK was utilized for this study. Clinical isolates were obtained 
from six patients: pre-treatment and post-treatment samples were available for patients HL1204, HL1205, 
HL1209, HL1210 and HL1211 and only pre-treatment for patient HL1212. Details of the patient history, para-
sitaemia and treatment have previously been published3. Eighteen paired dried blood spot (DBS) samples were 
available to validate the HRM on DBS field samples. For 15 children, day 0 (before treatment) and day 7 (7 days 
after treatment) were available. For two children, day 0 and day 14 or day 28 samples were available and for one 
child, day 0, 7 and 21 samples were available. The samples were collected between January and July 2014 from 
asymptomatic children aged 5 to 12 years attending schools near Mbita, Kenya, as part of a study on mosquito 
behaviour and odor profile of malaria-infected individuals. Study site, sample collection and other details of the 
Figure 4. msp1 HRM analysis of paired clinical samples from the same individuals. Melting amplification 
curves (top graphs) and normalized temperature-shifted HRM amplification curves (bottom graphs) of msp1 
genotypes in 5 patients sampled before (hr 0) and after treatment (hr 13–48). Differences in raw florescence 
signal between timepoints were observed, but didn’t affect HRM genotype calls after normalization. dF/dT, 
negative derivative of change in florescence and C°, temperature.
Figure 5. msp2 HRM analysis of paired clinical samples from the same individuals. Melting amplification 
curves (top graphs) and normalized temperature-shifted HRM amplification curves (bottom graphs) of msp2 
genotypes in 5 patients sampled before and after treatment.
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study has already been published21,22. Culture adapted laboratory isolates 3D7, Dd2, 7G8, K1, R033 and D10 were 
obtained from the Malaria Research and Reference Reagent Repository (http://MR4.org). Parasite cultures were 
tightly synchronized as ring-stage trophozoites to stimulate infected peripheral blood in vivo.
PCR. New primer sets were designed to amplify block 1 of msp1 and block 3 of msp2 genes. Pairs of oligonucleotide 
primers for msp1 (Msp1HRM_F: TAGAAGATGCAGTATTGACAGGT and Msp1HRM_R: CAGCGTAA 
GATTTAGCATCTGAATC) and msp2 (Msp2HRM_F: AGCAACACATTCATAAACAATGCT) and Msp2HRM_ 
R: TCCATGTTGTCCTGTACCTTTATTC) flanking the target regions were designed with the PCR amplicon 
expected to yield 346 bp and 518 bp respectively. The msp1 primers are conserved in the commonly used iso-
lates K1, MAD20 and Ro33, and the msp2 primers in FC27 and 3D7/IC respectively. Amplification of DNA was 
performed in a 25 µl reaction volume on a Rotor-gene 6000 thermal cycler (QIAGEN, Germany). The reaction 
mixture contained 5 µl of extracted genomic DNA, 200 nM of each primer, 3 mM of MgCl2, 300 nM of each dNTP, 
5 µM SYTO 9 green florescence nucleic acid stain (Invitrogene), 1X NH4 reaction buffer (Bioline, UK) and 1 U 
Taq polymerase (Biolione, UK). PCR conditions were one cycle of 94 °C for 2 min, 40 cycles of 94 °C for 15 sec, 
Patient 
ID
Time after 
treatment
Genotype called by the 
software compared to hr 0
Msp1 Confidence 
% relative to hr 0
Msp2 Confidence 
% relative to hr 0
HL 1204
hr 0 HL1204 99.53 99.41
hr 18 HL1204 82.17 82.95
hr 45 HL1204 59.52 55.65
HL 1205
hr 0 HL1205 98.59 90.75
hr 15 Variation <50 <50
hr 36 HL1205 70.27 Negative
HL 1209
hr 0 HL1209 99.77 98.72
hr 13 HL1209 56.35 69.63
hr 37 HL1209 57.80 <50
HL 1210
hr 0 HL1210 94.75 98.52
hr 15 HL1210 73.23 74.35
hr 40 Negative NA NA
HL 1211
hr 0 HL1211 99.83 95.89
hr 24 HL1211 65.63 88.57
hr 48 HL1211 77.51 94.24
Table 2. Genotype calling of paired clinical samples using GCP* of msp1 and msp2. All clinical samples after 
treatment had the same genotype compared to their corresponding samples before treatment (hr 0) samples 
with a GCP of more than 50%. Exceptions are HL1205 and HL1209, where both had a post-treatment genotype 
different from the pre-treatment in one or more loci. A second time-point after treatment was included for 
comparison purposes and in order to further evaluate the performance of msp1 and msp2 HRM genotyping for 
low parasitaemia samples. *GCP, Genotype Confidence Percentage, percentage of similarity of post-treatment 
sample to its corresponding pre-treatment sample.
Figure 6. Benefits of msp1 and msp2 genotyping by real-time PCR and HRM. Summary of significant gains in 
simplicity, speed and interpretation of results from utilizing the qPCR-HRM genotyping approach compared 
to the conventional msp1 and msp2 genotyping using gel electrophoresis. *3–4 hours per run (72 samples for 
rotor-gene and 96 samples for other platforms).
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54 °C for 20 sec and 72 °C for 40 sec. To verify the specificity of the primer sets, PCR products were detected by gel 
electrophoresis of 10 µl from each reaction on 2% agarose gels. Gel-based PCR assays targeting msp1 and msp2 
genes were amplified using previously reported methods6 and clone similarity between time points was carried 
out using previously published approaches5,18. Gels were made and run in TBE buffer (sigma-Aldrich, UK) and 
5ul of loading buffer (Bioline, UK) were added to each sample prior to electrophoresis.
Optimization and validation. The specificity of the msp1 and msp2 primers was established by running 
gel-electrophoresis of the PCR products. The sensitivity and limit of detection of the assay was estimated using 
a five-fold serial dilution of 3D7 in blood starting at 3% parasitaemia. The sensitivity to detect clones in mixed 
infection was estimated using a mixture of Dd2 and 7G8, and Dd2 and K1 Plasmodium falciparum in culture 
medium at 5% haematocrite in a ratio of 1:1, 10:1, 25:1, 50:1, 100:1, 500:1 and 1000:1, and Dd2:7G8 in a ratio of 
1:1, 10:1, 25:1, 50:1, 100:1, 500:1 and 1000:1 with a minimum parasitaemia of 15 parasites per µl. The reproduc-
ibility of the msp1 and msp2 HRM assays was determined by carrying out 35 replicate tests of 15 parasites per µl 
of 3D7 strain.
HRM curve acquisition. QPCR HRM analysis was performed in a Rotor-gene 6000 thermal cycler (Corbett 
Life Science). In order to determine the optimal melting temperature for differentiation of P. falciparum clones, 
the PCR products were subjected to a ramping of 0.1 °C s−1 between 75 °C and 90 °C. All specimens were per-
formed in duplicate and their melting profiles were analysed using Rotor-gene 6000 software (version 1.7.87) 
and the HRM algorithm provided. Visual examination of the melt curves data from a panel of laboratory isolates 
across a gradient of different temperature ramp increments was performed to select the optimum temperature in 
which most laboratory isolates show distinct conventional melt curves.
Genotyping analysis. For genotype analysis, temperature-shifted and normalized amplification curves were 
used in in the HRM analysis. Normalization regions of 82.0–82.5 and 88.0–88.5 were used as a standard but were 
modified for some clinical samples depending on the melting temperature peaks observed. The threshold in the 
melting curve analysis was adjusted to ensure that all positive samples generate interpretable dF/dT profiles and 
melt peak estimates. A fixed threshold was not deployed as the florescence signal amplitude varied across sam-
ples. The Genotype Confidence Percentage (GCP) is a value attributed to each genotype/allele compared with the 
genotype of a calibrator, with a value of 100% indicating an exact match. For clinical samples, the pre-treatment 
sample (hr 0) was a calibrator.
Clonal and cluster analysis. Melt curve analysis was used to verify the presence of multiple clones in each 
parasite isolate or culture. Clone similarity was signified by assigning names of known genotypes (strains) to sam-
ples with similar melting temperature to the known genotypes. PCR amplicons from five different P. falciparum 
laboratory isolates were subjected to HRM curve analysis. The difference-curve graph was used to classify the dif-
ferent msp1 and msp2 clones into clusters based on florescence signal difference relative to K1 (reference strain).
Analysis methods. Validation of each result was assessed using CT value, end-point florescence level and 
amplification efficiency. The real-time data were analysed using different modules available in the Rotor-gene 
software. A sample was re-analysed if its CT value was ≥30, or if it had lower amplification end point compared to 
the majority plots, or if amplification efficiency differ from other reactions or fell below an amplification value of 
1.4 (2 = 100% amplification efficiency). The reproducibility of the msp1 and msp2 assays was measured by calcu-
lating the coefficient of variation (mean ± standard deviation) of GCP of replicate tests.
Availability of data and material. All culture-adapted parasite lines described have been deposited in the 
European Malaria Reagent Repository (http://www.malariaresearch.eu/) and are freely available to researchers. 
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
Ethics approval and consent to participate. All research was performed in accordance with LHSTM 
relevant guidelines. Voluntary informed written consent and travel history was obtained from patients presenting 
with malaria to the HTD, or the Accident and Emergency Department of University College London Hospitals 
(UCLH). Approval for the study was obtained from the Research Ethics Committee of the University College 
London Hospitals (Application number: 07/Q0505/60), and include in their manuscript a statement confirming 
that informed consent was obtained from all participants and/or their legal guardians
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